Prescription medicine

Enalaprilat First approved as Vasotec

Enalaprilat (Vasotec) is a prescription medicine with an FDA approval on record since 1988. FDA's NDC Directory lists it from 3 generic labelers.

Generic listed
Boxed warning

Check it at the source: the enalaprilat FDA label on DailyMed (effective June 7, 2024, Dr. Reddys Laboratories Inc); the NDA 19309 record on Drugs@FDA; every enalaprilat label on DailyMed.

Highlights of the record

FDA label of June 7, 2024; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026

Boxed warning

IN PREGNANCY.

When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, enalaprilat injection should be discontinued as soon as possible. See WARNINGS, Fetal/Neonatal Morbidity and Mortality.

Used for

From the label: indications and usage
Enalaprilat injection is indicated for the treatment of hypertension when oral therapy is not practical.

Forms and strengths

1.25 mg/ml
2.5 mg/2ml

Injection.

On the market

Earliest approval on file: February 9, 1988 Vasotec, Biovail Labs Intl; Drugs@FDA’s file, where older or withdrawn approvals can be missing
Generic approvals: 6 first August 22, 2000; 3 with a marketed status in Drugs@FDA
Labelers listed (NDC): 3 of which 3 under generic applications, 0 under brand applications, repackagers included

Supply and safety

Pharmacy cost (NADAC): Not in the survey
Shortage (FDA): No current entry
Recalls by its makers (FDA): No recall recorded
FAERS reports: 250 through July 30, 2026

What is enalaprilat used for?

From the label: indications and usage
Enalaprilat injection is indicated for the treatment of hypertension when oral therapy is not practical. Enalaprilat injection has been studied with only one other antihypertensive agent, furosemide, which showed approximately additive effects on blood pressure. Enalapril, the pro-drug of enalaprilat, has been used extensively with a variety of other antihypertensive agents, without apparent difficulty except for occasional hypotension. […]

Conditions named in the indications of enalaprilat's FDA labels, with every medicine labeled for each:

High blood pressure

From other enalaprilat labels
High blood pressure: INDICATIONS AND USAGE Enalaprilat injection is indicated for the treatment of hypertension when oral therapy is not practical.

FDA pharmacologic class: Angiotensin Converting Enzyme Inhibitor.

Source: FDA drug label (Enalaprilat), Dr. Reddys Laboratories Inc, effective June 7, 2024 (SPL set 5d398da1-020c-ccb1-a775-ce8e0b29d621), via openFDA; the full label on DailyMed

Is there a generic for enalaprilat (Vasotec)?

The FDA approved the first generic enalaprilat on August 22, 2000. 6 generic applications are approved; 3 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.

FDA's NDC Directory lists enalaprilat from 3 labelers under a generic (ANDA) application. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.

1988 earliest approval on file
2000 first generic approved

Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)

What does the enalaprilat label say about other medicines?

The enalaprilat label names 12 other medicines in its interaction, contraindication or warning sections. The labels of 1 other medicine name enalaprilat. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.

Medicine named	Section	What the label says
Amiloride	drug interactions	Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
Captopril	warnings	Neutropenia/Agranulocytosis Another angiotensin-converting enzyme inhibitor, captopril, has been shown to cause agranulocytosis and bone marrow depression, rarely in uncomplicated patients but more frequently in patients with renal impairment especially if they also have a collagen vascular disease.
Enalapril	drug interactions	Non-Steroidal Anti-Inflammatory Agents: In some patients with compromised renal function who are being treated with non-steroidal anti-inflammatory drugs, the coadministration of enalapril may result in a further deterioration of renal function.
Epinephrine	warnings	Where there is involvement of the tongue, glottis or larynx, likely to cause airway obstruction, appropriate therapy, e.g., subcutaneous epinephrine solution 1:1000 (0.3 mL to 0.5 mL) and/or measures necessary to ensure a patent airway, should be promptly provided (see ADVERSE REACTIONS ).
Hydralazine	drug interactions	Other Cardiovascular Agents: Enalaprilat injection has been used concomitantly with digitalis, beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine and prazosin without evidence of clinically significant adverse interactions.
Indomethacin	drug interactions	In a clinical pharmacology study, indomethacin or sulindac was administered to hypertensive patients receiving enalapril maleate.
Lithium	drug interactions	Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.
Methyldopa	drug interactions	Other Cardiovascular Agents: Enalaprilat injection has been used concomitantly with digitalis, beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine and prazosin without evidence of clinically significant adverse interactions.
Prazosin	drug interactions	Other Cardiovascular Agents: Enalaprilat injection has been used concomitantly with digitalis, beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine and prazosin without evidence of clinically significant adverse interactions.
Spironolactone	drug interactions	Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
Sulindac	drug interactions	In a clinical pharmacology study, indomethacin or sulindac was administered to hypertensive patients receiving enalapril maleate.
Triamterene	drug interactions	Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.

Other labels that name enalaprilat

Tenapanor

Check enalaprilat against other medicines

Source: FDA drug label (Enalaprilat), Dr. Reddys Laboratories Inc, effective June 7, 2024 (SPL set 5d398da1-020c-ccb1-a775-ce8e0b29d621), via openFDA; the full label on DailyMed

What do FAERS reports show for enalaprilat?

The FDA Adverse Event Reporting System holds 250 reports that list enalaprilat among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 29 are coded as a death and 113 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.

The most reported reactions

Heart Rate Decreased19
Blood Pressure Systolic Abnormal18
Blood Pressure Systolic Increased18
Joint Swelling18
Oxygen Saturation Decreased18
Blood Pressure Diastolic Decreased17
Nausea (named in the label)17
Fall15

Side effects: the label's list and every FAERS reaction

Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026

What else is labeled for the same conditions as enalaprilat?

4 other medicines are given the same way (intravenous) and in the same FDA class as enalaprilat or labeled mainly for the same use (high blood pressure), the same class first. High blood pressure lists all 88 medicines labeled for it, by any route. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.

Medicine	Shared indication	Generic labelers (intravenous)	Pharmacy cost	Shortage
Esmolol	High blood pressure	12 labelers	n/a	No current entry
Nicardipine	High blood pressure	16 labelers	n/a	No current entry
Labetalol	High blood pressure	15 labelers	$0.185 per mL 100 mg/20 mL vial	No current entry
Metoprolol	High blood pressure	14 labelers	n/a	A presentation being discontinued

Every medicine labeled for the same conditions as enalaprilat

Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)

What next?

Alternatives to enalaprilat: 4 medicines for the same use
Other ACE inhibitors: the pharmacologic class, with prices and generics
Enalaprilat side effects: the label's list beside FAERS reports
Check an interaction: what two or more labels say about each other